Frank Cerra

Policy

Vision unrealized? University of Minnesota faces new reality

Dr. Frank Cerra has hitched his wagon to outgoing University of Minnesota president Robert Bruininks. Cerra, medical school dean and head of the school's Academic Health Center, is retiring at the end of the year partly because Bruininks is doing the same. It's just as well. Together, the two men had sought to remake the school into a top research university and an economic engine for Minnesota. But as they prepare to exit, their vision is in doubt.

By Thomas Lee
sponsored content

A Deep-dive Into Specialty Pharma

A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.

By PurpleLab
News

Where does the Minnesota Science Park leave the UEL?

UEL, after all, hosts the university's Office for Technology Commercialization and hopes to serve as an incubator for companies originating from technology created by school's Medical Device Innovation Fellowship Program. UEL also is located close enough to MSP that it seems perfectly natural to imagine a technology corridor stretching from Biomedical Discovery District and MSP in Minneapolis to UEL in St. Paul.

By Thomas Lee